Prothena Corporation plc

Healthcare · Biotechnology · Ireland

Last price 8.47 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 434.82M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau a...